Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delirium in patients with advanced cancer.

The Lancet. Oncology·2016
Same author

THE RISE OF THE CHIEF EXPERIENCE OFFICER.

Physician leadership journal·2015
Same author

Road To Developing Regulatory Pathway For Biologic Follow-ons Has Many Turns.

Biotechnology healthcare·2013
Same author

Approvals, FDA actions, clinical trials.

Biotechnology healthcare·2013
Same author

HCV testing cost-effective alternative to treating advanced disease.

Biotechnology healthcare·2013
Same author

Approvals, FDA actions, clinical trials.

Biotechnology healthcare·2013
Same journal

Big pharma moves into biologics.

Biotechnology healthcare·2013
Same journal

Study: High Copayments Cut Biodrug Use up to 21 Percent.

Biotechnology healthcare·2013
Same journal

Avian flu and the quest for immunity: not just chicken feed.

Biotechnology healthcare·2013
Same journal

Variety of Biotech Therapies, Uses Take Prominence Among ASCO Presentations.

Biotechnology healthcare·2013
Same journal

Opening the door to follow-on proteins?

Biotechnology healthcare·2013
Same journal

On specialty pharmaceuticals: reflections of a second-year medical student.

Biotechnology healthcare·2013
See all related articles

Related Experiment Video

Updated: May 23, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

A wish list for molecular tests.

Bob Carlson

    Biotechnology Healthcare
    |April 6, 2012
    PubMed
    Summary
    This summary is machine-generated.

    Companion diagnostics can enhance patient health outcomes. However, payers and clinicians require more long-term benefit data, while the FDA seeks regulatory control, delaying patient access.

    More Related Videos

    Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1
    06:18

    Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

    Published on: March 13, 2018

    Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
    05:58

    Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

    Published on: August 20, 2018

    Related Experiment Videos

    Last Updated: May 23, 2026

    Comparative Lesions Analysis Through a Targeted Sequencing Approach
    08:16

    Comparative Lesions Analysis Through a Targeted Sequencing Approach

    Published on: November 5, 2019

    Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1
    06:18

    Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

    Published on: March 13, 2018

    Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
    05:58

    Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

    Published on: August 20, 2018

    Area of Science:

    • Biomarker-driven personalized medicine
    • Regulatory science in healthcare
    • Health economics and outcomes research

    Background:

    • Companion diagnostics (CDx) are crucial for targeted therapies, improving patient outcomes.
    • Industry stakeholders are ready to collaborate with payers on coverage policies.
    • Existing evidence focuses on short-term benefits, necessitating more long-term data.

    Purpose of the Study:

    • To explore the challenges and opportunities in companion diagnostics adoption.
    • To address the need for robust long-term evidence for payers and clinicians.
    • To examine the evolving regulatory landscape for companion diagnostics.

    Main Methods:

    • Qualitative analysis of industry perspectives and regulatory trends.
    • Review of current literature on companion diagnostics' long-term impact.
    • Stakeholder interviews (developers, payers, clinicians, regulators).

    Main Results:

    • Developers express willingness to partner with payers for policy development.
    • Payers and clinicians emphasize the need for comprehensive long-term efficacy and cost-effectiveness data.
    • Regulatory bodies, including the FDA, are actively defining their oversight roles.

    Conclusions:

    • Balancing innovation with evidence generation is key for companion diagnostics.
    • Collaborative efforts are needed to establish clear pathways for coverage and regulatory approval.
    • Timely patient access to companion diagnostics hinges on addressing payer, clinical, and regulatory demands.